December 28, 2025 04:07 am (IST)
Follow us:
Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
New Delhi, June 23 (IBNS) Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Levofloxacin Tablets, 250mg and 500mg, the generic version of Levaquin Tablets (of Ortho-McNeil), which is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.
The total market size for Levofloxacin Tablets as per IMS is $28 Million per annum.
As on Mar 31, Jubilant Life Sciences had a total of 806 filings for formulations of which 368 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Coforge just acquired Silicon Valley AI firm Encora — Here’s why it could shake up the tech market
Sat, Dec 27 2025
Big win: Tata Chemicals enters CII’s elite top 50 innovators list
Fri, Dec 26 2025
Ola Electric skyrockets! Shares jump 5% on Rs 367 crore PLI windfall
Fri, Dec 26 2025
Big govt boost for Ola Electric! Rs 367 cr PLI sanction clears path to profitability
Fri, Dec 26 2025
Dream job alert: Infosys entry-level packages skyrocket to ₹21 lakh
Thu, Dec 25 2025